Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Struggling with Staying Informed? In the fast-paced world of diagnostic medicine, staying updated with the latest legal, compliance, regulatory, and industry insights is crucial. Yet, finding reliable and comprehensive information can be overwhelming and time-consuming.
Lab Industry Advisor to the Rescue! Lab Industry Advisor provides comprehensive, up-to-date insights and analyses tailored to your needs. With expert commentary and actionable advice, you’ll stay ahead of the curve. No more sifting through endless sources—everything you need is right here!
Start your free trial today and see how Lab Industry Advisor can transform your approach. Get instant access to invaluable resources designed to keep you informed and competitive. Explore detailed reports, in-depth articles, and exclusive industry insights that help you make better decisions faster. Choose from three subscription levels tailored to fit your needs: Essential, Premium, and Elite.
![Essential](https://www.g2intelligence.com/wp-content/uploads/2023/11/Essential.png)
![62934_G2_Subscription Website Images_JL V1](https://www.g2intelligence.com/wp-content/uploads/2023/11/62934_G2_Subscription-Website-Images_JL-V1.png)
![Special-Report](https://www.g2intelligence.com/wp-content/uploads/2023/11/Special-Report.png)
![62934_G2_Subscription Website Images_JL V12](https://www.g2intelligence.com/wp-content/uploads/2023/11/62934_G2_Subscription-Website-Images_JL-V12.png)
![Special-Analysis](https://www.g2intelligence.com/wp-content/uploads/2023/11/Special-Analysis.png)
![Elite](https://www.g2intelligence.com/wp-content/uploads/2023/11/Elite.png)
Additional Business Intelligence Offerings
Lab Industry Advisor Subscriptions Include
![paper_magnifing_glass_512](https://www.g2intelligence.com/wp-content/uploads/2023/11/paper_magnifing_glass_512.png)
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
Quest CEO Outlines Growth Strategies for a Changing Market
By Stephanie Murg, Managing Director, G2 Intelligence The nation’s largest provider of laboratory services is not waiting to react to the changing dynamics of healthcare but is balancing aggressive cost-cutting with a decisive focus on diagnostic information...
FDA to Hold Public Workshop on Next Generation Sequencing
By Kelly A. Briganti, Editorial Director, G2 Intelligence Next Generation Sequencing (NGS) diagnostic tests bring incredible opportunities for patient care, yet at the same time present significant challenges for oversight. Recognizing these challenges and...
CMS Says More Data On the Way
By Christopher P. Young, Editor, G2 Compliance Advisor In spite of objections from the American Medical Association (AMA), a Centers for Medicare and Medicaid Services (CMS) spokesperson told a Wall Street Journal (WSJ) reporter that it intends to publish annual...
Laboratory Medicine Shifting Away from Academic Orientation
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Increasingly, the practice of laboratory medicine is burdened by administrative responsibilities leaving less time for research among academic clinical chemists (laboratory physicians and...
Guilty Pleas In Biodiagnostic Case Reach 35
By Ron Shinkman, Editor, Laboratory Industry Report A Jersey City, NJ physician has become the latest person to plead guilty for his part in a kickback scheme involving Parsippany, NJ-based Biodiagnostic Laboratory Services. Anthony DelPiano, M.D., admitted in...
FY 2016 Budgets Target Diagnostic Testing and Compliance Issues
By Kelly A. Briganti, JD, Editorial Director, G2 Intelligence Government agencies that impact the laboratory industry have submitted budgets for fiscal year 2016 that will fund efforts to reduce healthcare spending, focus on quality of care rather than quantity,...
MetaStat Enters Into Tissue Deal With Kaiser Hospitals
By Ron Shinkman, Editor, Laboratory Industry Report MetaStat, the Boston-based molecular laboratory startup, has entered into an agreement to obtain a large cache of both tissue samples and deidentified patient data. Under the terms of the deal, Kaiser Foundation...
Thermo Fisher, Cynvenio Partner as Liquid Biopsy Technology Expands
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Thermo Fisher Scientific (Carlsbad, Calif.) and Cynvenio Biosystems (Westlake Village, Calif.) have signed a distribution agreement for the LiquidBiopsy platform. The combination of Cynvenio’s...
Medicare Announces Timeline for Shifting from Volume to Value Based Reimbursement
By Kelly A. Briganti, JD, Editorial Director G2 Intelligence There has been much discussion about moving away from fee for service reimbursement and the need to tie reimbursement to the value provided, rather than the amount of care provided. That discussion takes...
The New 59 X(EPSU) Modifiers, X’d For Now
By Christopher P. Young, Editor, G2 Compliance Advisor The latest communication from the Centers for Medicare and Medicaid Services (CMS) concerning new modifiers, referred to as X(EPSU), intended to replace the 59 modifier, says that while the new modifiers are...